Sanofi and Regeneron Pharmaceuticals have announced that the phase IIa study of dupilumab in asthma was named "Clinical Advance of the Year" by Scrip Intelligence at the 9th annual Scrip Awards. The award was announced last week by Scrip, a pharmaceutical industry publication.
Dupilumab is a fully-human monoclonal antibody that is being developed by Regeneron and Sanofi for the treatment of asthma, atopic dermatitis and nasal polyposis.
George D. Yancopoulos, M.D., Ph. D., chief scientific officer of Regeneron and president of Regeneron Laboratories, said, "We appreciate the recognition by Scrip that dupilumab is one of the most exciting emerging clinical candidates in the industry. We feel that this award is additional validation of the overall depth and productivity of our R&D team and the powerful VelociSuite technologies they employ, which have delivered dupilumab and several other investigational therapeutic opportunities."
Award winners were selected by a 15-member panel of pharmaceutical industry executives, consultants and researchers.